Get the Stockscreener App
9.42
0.75%
0.07
Pre-market:
9.16
-0.26
-2.76%
Neogenomics Inc stock is traded at $9.42, with a volume of 2.25M.
It is up +0.75% in the last 24 hours and down -5.71% over the past month.
See More
Previous Close:
$9.35
Open:
$9.13
24h Volume:
2.25M
Relative Volume:
1.89
Market Cap:
$1.20B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-15.19
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+0.11%
1M Performance:
-5.71%
6M Performance:
-34.31%
1Y Performance:
-36.39%
1-Day Range:
$9.13
$9.66
1-Week Range:
$9.00
$9.71
52-Week Range:
$9.00
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
9.42 | 1.20B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
489.06 | 182.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.16 | 143.37B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
426.25 | 33.92B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
115.99 | 33.08B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
174.37 | 30.19B | 15.41B | 1.37B | 2.11B | 7.50 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019 - ACCESS Newswire
NeoGenomics announces CEO transition - MSN
New CEO assumes role at NeoGenomics - Gulfshore Business
NeoGenomics appoints Tony Zook as CEO - Investing.com
NeoGenomics, Inc. Announces CEO Changes - MarketScreener
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics - BioSpace
NeoGenomics appoints Tony Zook as CEO By Investing.com - Investing.com Australia
NeoGenomics Appoints Tony Zook Chief Executive - MarketScreener
NeoGenomics' New CEO Zook Takes Over as Smith Retires - MarketWatch
Tony Zook Assumes Role As Chief Executive Officer Of Neogenomics - MarketScreener
Diagnostic Leader NeoGenomics Taps 30-Year Veteran to Drive Oncology Testing Growth - Stock Titan
Benchmark maintains Hold on Neogenomics stock, reiterates price target By Investing.com - Investing.com Canada
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
3 Reasons to Sell NEO and 1 Stock to Buy Instead - Yahoo Finance
Piper Sandler maintains Neogenomics stock with $18 target - Investing.com
Piper Sandler maintains Neogenomics stock with $18 target By Investing.com - Investing.com UK
NeoGenomics elevates Warren Stone to President and COO By Investing.com - Investing.com Australia
NeoGenomics Promotes Warren Stone to President & COO - TipRanks
Fort Myers-based NeoGenomics names new COO - Gulfshore Business
Earnings call transcript: NeoGenomics Q4 2024 results disappoint despite EPS beat - Investing.com
NeoGenomics elevates Warren Stone to President and COO - Investing.com
NeoGenomics Names Warren Stone President, COO -March 18, 2025 at 08:09 am EDT - Marketscreener.com
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer - Lelezard
NeoGenomics Appoints Warren Stone As President & Chief Operating Officer -March 18, 2025 at 07:10 am EDT - Marketscreener.com
Commit To Buy NeoGenomics At $8, Earn 19.6% Annualized Using Options - Nasdaq
NeoGenomics (NASDAQ:NEO) Stock Price Up 7.2%Here's What Happened - MarketBeat
SBI Securities Co. Ltd. Invests $26,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics at Barclays Healthcare: Strategic Focus on Innovation - Investing.com India
Bank of New York Mellon Corp Purchases 15,269 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.60 Average Target Price from Analysts - Defense World
NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth By Investing.com - Investing.com South Africa
(NEO) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth - Investing.com
Fort Myers-based NeoGenomics expands cancer testing reach with acquisition - News-Press
Proficio Capital Partners LLC Invests $372,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
BTIG maintains $17 target on Neogenomics stock post-acquisition By Investing.com - Investing.com UK
NeoGenomics Acquires Pathline -March 10, 2025 at 08:13 am EDT - Marketscreener.com
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline - BioSpace
NeoGenomics expands with Pathline acquisition - Investing.com India
NeoGenomics expands with Pathline acquisition By Investing.com - Investing.com South Africa
NeoGenomics Expands Oncology Testing Reach In The Northeast With Acquisition Of Pathline - Marketscreener.com
Smartleaf Asset Management LLC Has $70,000 Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R) - ACCESS Newswire
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
NeoGenomics price target lowered to $17 from $18 at BTIG - MSN
NeoGenomics at TD Cowen Conference: CEO Transition and Growth Plans By Investing.com - Investing.com UK
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Truist Financial Corp - Defense World
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes - ACCESS Newswire
NeoGenomics Announces Leadership Team Transition - ACCESS Newswire
Investor Network Invites You to the NeoGenomics First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, April 26, 2017 - ACCESS Newswire
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):